Fly News Breaks for February 24, 2020
Feb 24, 2020 | 06:15 EDT
BofA analyst Jason Gerberry downgraded Galapagos to Underperform from Neutral with an unchanged $213 price target, citing its valuation and risk-reward profile. The analyst notes that the company's operating expense is about 15%-20% higher than he previously expected, and sees the royalty revenue opportunity on filgotinib for rheumatoid arthritis as having already been priced into consensus sales up to FY25. Gerberry adds that he is concerned with the company being able to support its implied platform valuation ahead of its "risky" clinical trial data.
News For GLPG From the Last 2 Days
There are no results for your query GLPG